Breaking News
FLASH SALE 0
⚡ FLASH SALE: Spot opportunities like a pro? Here's one: InvestingPro at 50% off
Claim sale
Close

Cullinan Oncology LLC (CGEM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cullinan Oncology LLC's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.30 -0.24    -2.81%
25/03 - Closed. Currency in USD
Pre Market
8.11
-0.19
-2.29%
8:32:03 - Real-time Data
  • Volume: 365,956
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 8.23 - 8.54
Type:  Equity
Market:  United States
Cullinan Oncology LLC 8.30 -0.24 -2.81%

Cullinan Oncology LLC Company Profile

 
Read the Cullinan Oncology LLC company profile to learn more about the business and the management team. View Cullinan Oncology LLC facts about how many employees Cullinan Oncology LLC has, CGEM company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

111

Equity Type

ORD

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address One Main Street Suite 1350
Cambridge, 02142
United States
Phone 617 410 4650
Fax -

Top Executives

Name Age Since Title
Anthony A. Rosenberg 70 2017 Independent Chairman of the Board
Nadim Ahmed 55 2021 President, CEO & Director
Patrick A. Baeuerle 66 2022 Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
Ronald Levy - 2023 Member of Scientific Advisory Board
David McDermott - 2023 Member of Scientific Advisory Board
Anthony W. Tolcher - 2023 Member of Scientific Advisory Board
Stephen W. Webster 63 2020 Independent Director
Anne-Marie Martin 52 2022 Independent Director
Bahija Jallal 63 2023 Member of Scientific Advisory Board
Patricia LoRusso - 2023 Member of Scientific Advisory Board
David P. Ryan 57 2022 Independent Director
David D. Meek 61 2024 Independent Director
Mary T. Thistle 64 2024 Director
Chaim Putterman - 2024 Member of Scientific Advisory Board
Mario Sznol - 2024 Member of Scientific Advisory Board
Ricardo Grieshaber-Bouyer - 2024 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Cullinan Oncology LLC (CGEM) Price Discussion

Write your thoughts about Cullinan Oncology LLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email